177 related articles for article (PubMed ID: 36565756)
1. Development of a robust and convenient dual-reporter high-throughput screening assay for SARS-CoV-2 antiviral drug discovery.
Chiu W; Schepers J; Francken T; Vangeel L; Abbasi K; Jochmans D; De Jonghe S; Thibaut HJ; Thiel V; Neyts J; Laporte M; Leyssen P
Antiviral Res; 2023 Feb; 210():105506. PubMed ID: 36565756
[TBL] [Abstract][Full Text] [Related]
2. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 replicon for high-throughput antiviral screening.
Zhang QY; Deng CL; Liu J; Li JQ; Zhang HQ; Li N; Zhang YN; Li XD; Zhang B; Xu Y; Ye HQ
J Gen Virol; 2021 May; 102(5):. PubMed ID: 33956592
[TBL] [Abstract][Full Text] [Related]
4. Generation of SARS-CoV-2 reporter replicon for high-throughput antiviral screening and testing.
He X; Quan S; Xu M; Rodriguez S; Goh SL; Wei J; Fridman A; Koeplinger KA; Carroll SS; Grobler JA; Espeseth AS; Olsen DB; Hazuda DJ; Wang D
Proc Natl Acad Sci U S A; 2021 Apr; 118(15):. PubMed ID: 33766889
[TBL] [Abstract][Full Text] [Related]
5. Monitoring SARS-CoV-2 Infection Using a Double Reporter-Expressing Virus.
Chiem K; Park JG; Morales Vasquez D; Plemper RK; Torrelles JB; Kobie JJ; Walter MR; Ye C; Martinez-Sobrido L
Microbiol Spectr; 2022 Oct; 10(5):e0237922. PubMed ID: 35980204
[TBL] [Abstract][Full Text] [Related]
6. An optimized high-throughput SARS-CoV-2 dual reporter trans-complementation system for antiviral screening in vitro and in vivo.
Li Y; Tan X; Deng J; Liu X; Liu Q; Zhang Z; Huang X; Shen C; Xu K; Zhou L; Chen Y
Virol Sin; 2024 Jun; 39(3):447-458. PubMed ID: 38548102
[TBL] [Abstract][Full Text] [Related]
7. Cell-Based High-Throughput Screening Protocol for Discovering Antiviral Inhibitors Against SARS-COV-2 Main Protease (3CLpro).
Rothan HA; Teoh TC
Mol Biotechnol; 2021 Mar; 63(3):240-248. PubMed ID: 33464543
[TBL] [Abstract][Full Text] [Related]
8. A dengue type 2 reporter virus assay amenable to high-throughput screening.
Li LH; Kaptein SJF; Schmid MA; Zmurko J; Leyssen P; Neyts J; Dallmeier K
Antiviral Res; 2020 Nov; 183():104929. PubMed ID: 32898584
[TBL] [Abstract][Full Text] [Related]
9. Construction of a Noninfectious SARS-CoV-2 Replicon for Antiviral-Drug Testing and Gene Function Studies.
Nguyen HT; Falzarano D; Gerdts V; Liu Q
J Virol; 2021 Aug; 95(18):e0068721. PubMed ID: 34191580
[TBL] [Abstract][Full Text] [Related]
10. A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry.
Xu M; Pradhan M; Gorshkov K; Petersen JD; Shen M; Guo H; Zhu W; Klumpp-Thomas C; Michael S; Itkin M; Itkin Z; Straus MR; Zimmerberg J; Zheng W; Whittaker GR; Chen CZ
SLAS Discov; 2022 Mar; 27(2):86-94. PubMed ID: 35086793
[TBL] [Abstract][Full Text] [Related]
11. A novel cell culture system modeling the SARS-CoV-2 life cycle.
Ju X; Zhu Y; Wang Y; Li J; Zhang J; Gong M; Ren W; Li S; Zhong J; Zhang L; Zhang QC; Zhang R; Ding Q
PLoS Pathog; 2021 Mar; 17(3):e1009439. PubMed ID: 33711082
[TBL] [Abstract][Full Text] [Related]
12. Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2.
Park JG; Oladunni FS; Chiem K; Ye C; Pipenbrink M; Moran T; Walter MR; Kobie J; Martinez-Sobrido L
J Virol Methods; 2021 Jan; 287():113995. PubMed ID: 33068703
[TBL] [Abstract][Full Text] [Related]
13. A high-throughput screening system for SARS-CoV-2 entry inhibition, syncytia formation and cell toxicity.
Jancy SV; Lupitha SS; Chandrasekharan A; Varadarajan SN; Nelson-Sathi S; Prasad R; Jones S; Easwaran S; Darvin P; Sivasailam A; Santhoshkumar TR
Biol Proced Online; 2023 Jul; 25(1):22. PubMed ID: 37495994
[TBL] [Abstract][Full Text] [Related]
14. A high throughput antiviral screening platform for alphaviruses based on Semliki Forest virus expressing eGFP reporter gene.
Shi YJ; Li JQ; Zhang HQ; Deng CL; Zhu QX; Zhang B; Li XD
Virol Sin; 2023 Aug; 38(4):585-594. PubMed ID: 37390870
[TBL] [Abstract][Full Text] [Related]
15. Orthogonal dual reporter-based gain-of-signal assay for probing SARS-CoV-2 3CL protease activity in living cells: inhibitor identification and mutation investigation.
Bei ZC; Yu H; Wang H; Li Q; Wang B; Zhang D; Xu L; Zhao L; Dong S; Song Y
Emerg Microbes Infect; 2023 Dec; 12(1):2211688. PubMed ID: 37144395
[No Abstract] [Full Text] [Related]
16. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.
David AB; Diamant E; Dor E; Barnea A; Natan N; Levin L; Chapman S; Mimran LC; Epstein E; Zichel R; Torgeman A
Molecules; 2021 May; 26(11):. PubMed ID: 34072087
[TBL] [Abstract][Full Text] [Related]
17. High-throughput screening assays for SARS-CoV-2 drug development: Current status and future directions.
Xu T; Zheng W; Huang R
Drug Discov Today; 2021 Oct; 26(10):2439-2444. PubMed ID: 34048893
[TBL] [Abstract][Full Text] [Related]
18. Development of a Single-Cycle Infectious SARS-CoV-2 Virus Replicon Particle System for Use in Biosafety Level 2 Laboratories.
Malicoat J; Manivasagam S; Zuñiga S; Sola I; McCabe D; Rong L; Perlman S; Enjuanes L; Manicassamy B
J Virol; 2022 Feb; 96(3):e0183721. PubMed ID: 34851142
[TBL] [Abstract][Full Text] [Related]
19. High-throughput drug screening using the Ebola virus transcription- and replication-competent virus-like particle system.
Lee N; Shum D; König A; Kim H; Heo J; Min S; Lee J; Ko Y; Choi I; Lee H; Radu C; Hoenen T; Min JY; Windisch MP
Antiviral Res; 2018 Oct; 158():226-237. PubMed ID: 30149038
[TBL] [Abstract][Full Text] [Related]
20. A High-Throughput, High-Containment Human Primary Epithelial Airway Organ-on-Chip Platform for SARS-CoV-2 Therapeutic Screening.
Fisher CR; Mba Medie F; Luu RJ; Gaibler RB; Mulhern TJ; Miller CR; Zhang CJ; Rubio LD; Marr EE; Vijayakumar V; Gabriel EP; Lopez Quezada L; Zhang CH; Anderson KS; Jorgensen WL; Alladina JW; Medoff BD; Borenstein JT; Gard AL
Cells; 2023 Nov; 12(22):. PubMed ID: 37998374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
